Definitive Contract 75N93025C00020
Award Date
6/1/25
Potential Completion Date
5/31/27
Potential Value
$600K
Federal Agency
National Institute of Allergy and Infectious Diseases
Awardee
Enepret Incorporated
Ultimate Awardee
Not listed
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Lexington, KY 40505, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
9
Legislative Mandate
Employment Eligibility Verification
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This $600,000 firm fixed price contract was awarded by the National Institutes of Health's National Institute of Allergy and Infectious Diseases to Adjuvax LLC of Birmingham, Alabama. The contract is being performed under SBIR Topic 106 to develop adjuvant mimics in support of the NIH and CDC's missions. The solicitation sought proposals for Small Business Innovation Research contracts across numerous technical topics aligned with improving public health. This award is set aside for total...
This federal contract award for $18,472,563.99 was issued by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), to the University of Montana. The contract's objective is to identify novel adjuvant candidates that can be used to augment the efficacy of human vaccines. Research under this definitive, cost-no-fee contract will contribute to the pipeline of new adjuvant leads that either exploit the innate immune system or act directly...
<p>Enepret Incorporated has been awarded a $3 million definitive contract from the National Institutes of Health National Institute of Allergy and Infectious Diseases to conduct Phase II Small Business Innovation Research work on the production of adjuvant mimics. The firm fixed price contract will be performed over a three year period in Lexington, Kentucky by Enepret's Enepret Division as the prime contractor. The contract is set aside for total small businesses.</p>
This is a $4,259,653.00 definitive contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH) within the Department of Health and Human Services (HHS), to Inimmune Corp, a biotechnology company, for the development of a synthetic AS01-like adjuvant system for influenza vaccines. The contract has an ultimate completion date of September 29, 2028 and is a cost-type contract without a fee. This contract is not set aside for...
This definitive contract was awarded by the National Institutes of Health's National Institute of Allergy and Infectious Diseases to Celdara Medical of Lebanon, New Hampshire. With a value of $599,977, the firm fixed price contract supports research under Solicitation Number NIH-CDC-SBIR-2019 in adjuvant development for vaccines against infectious or immune-mediated diseases. Specifically, the prime contractor will conduct work requested under Topic 081 of the solicitation, which sought small...
This definitive contract from the Department of Health and Human Services' National Institutes of Health and National Institute of Allergy and Infectious Diseases (HHS-NIH-NIAID) is valued at $600,000 to Antagen Biosciences Inc., doing business as Antagen Pharmaceuticals, for work in Boston, MA from September 2020 through August 2022. The contract was awarded under the Small Business Innovation Research (SBIR) program's total small business set-aside solicitation seeking proposals on topics...
The Department of Health and Human Services (HHS) National Institutes of Health (NIH) National Institute of Allergy and Infectious Diseases (NIAID) awarded a firm fixed price purchase order contract to Advanced Bioadjuvants, LLC, a self-certified small disadvantaged business. The contract is for license fees related to the Adjuplex trademark, patents, and trade secret manufacturing process, which NIAID will use to combine with human vaccines for clinical trials. The contract has a 12-month...
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $6,690,024.90 definitive, cost-no-fee contract to Vaxine PTY LTD, a for-profit organization located in Australia, for an Adjuvant Development Program. The contract, which has an ultimate completion date of February 10, 2025, was awarded on September 10, 2018 and does not have a set-aside designation. The contract aims to support the development of vaccine adjuvants, which are compounds that enhance the immune response to...
This is a $3,000,000 firm fixed-price Small Business Innovation Research (SBIR) Phase II contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID), a component of the National Institutes of Health (NIH), to Adjuvax LLC, a small disadvantaged and minority-owned business located in Birmingham, Alabama. The contract supports research and development under SBIR Topic 130, which focuses on discovering and down-selecting vaccine adjuvants for infectious and...
This is a $5,822,726 definitive federal contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID), a division of the National Institutes of Health, to Duke University for a project titled "ADJUVANT COMPARISON AND CHARACTERIZATION". The contract is for a 4-year period ending on June 30, 2026 and does not have a set-aside designation. Under this contract, Duke University will collaborate with subcontractors Inimmune Corp and the University of North Carolina at...